Raynaud's Disease Management

Introduction to Raynaud's Disease

• Raynaud's disease is a condition that affects blood flow to the fingers and toes, and can be primary or secondary, with secondary Raynaud's being a complication of an underlying condition such as systemic sclerosis or mixed connective tissue disease (MCTD) 1, 2

Diagnosis and Screening

• Delayed diagnosis of underlying connective tissue disease can lead to irreversible organ damage, highlighting the importance of early screening and diagnosis 1
• The European Heart Journal recommends echocardiographic screening in symptomatic patients with MCTD (Class I recommendation, Level C evidence) 3
• Right heart catheterization (RHC) is necessary to confirm the diagnosis in all cases of suspected PAH associated with MCTD, particularly if specific drug therapy is considered (Class I recommendation, Level C evidence) 3
• Exclusion of other causes of pulmonary hypertension, such as left heart disease (Group 2), lung diseases (Group 3), or chronic thromboembolic pulmonary hypertension (Group 4), is required 2
• The American College of Rheumatology recommends a detailed clinical history, physical examination during an attack, laboratory tests (including VSG, CRP, ANA, and specific autoantibodies), and capillaroscopy to diagnose Raynaud's phenomenon 4, 5

Pathophysiology and Classification

• Pulmonary arterial hypertension (PAH) associated with connective tissue diseases (CTD-PAH) is the second most prevalent type of PAH after idiopathic PAH, with MCTD representing a significant proportion of the remaining cases 2, 6
• The pathophysiological mechanisms of PAH in MCTD involve primary pulmonary arteriopathy similar to that seen in other CTDs 6
• Histopathological changes in PAH in MCTD are generally indistinguishable from classical idiopathic PAH 3
• PAH in MCTD is characterized by more frequent involvement of pulmonary veins compared to idiopathic PAH 3
• Immunological mechanisms, suggested by the presence of antinuclear antibody, rheumatoid factor, immunoglobulin G, and complement fraction deposits in the pulmonary vessels wall, play a role in PAH in MCTD 3

Treatment and Management

• The European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines recommend the same treatment algorithm for CTD-associated PAH as for idiopathic PAH (Class I recommendation, Level A evidence) 3
• Consideration of oral anticoagulation on an individual basis is recommended (Class IIa recommendation, Level C evidence) 3
• Non-pharmacological measures include cold avoidance strategies, use of gloves, avoiding direct contact with cold surfaces, smoking cessation, and stress management techniques, as well as exercise programs to improve overall circulation and function, as recommended by the American College of Rheumatology 7
• Calcium channel blockers, such as nifedipine, are commonly used as first-line treatment for secondary Raynaud's, but may cause adverse effects including hypotension, peripheral edema, and headaches, as noted by the European League Against Rheumatism 5, 1, 8, 9
• Phosphodiesterase-5 inhibitors, such as sildenafil and tadalafil, are second-line options for treating secondary Raynaud's, with topical nitrates, such as nitroglycerin and glyceryl trinitrate, used to treat secondary Raynaud's, but may cause headaches that limit adherence, as supported by the American College of Rheumatology 5, 1, 8, 9
• IV prostacyclin analogs, such as iloprost, are recommended for severe cases with digital ulcers, and endothelin receptor antagonists, such as bosentan, are specifically recommended for prevention of new digital ulcers in systemic sclerosis, as noted by the European League Against Rheumatism 1

Systemic Sclerosis

• Scleroderma is characterized by skin fibrosis, vasculopathy, and internal organ involvement affecting the lungs, gastrointestinal tract, heart, and kidneys, with clinical manifestations varying between limited and diffuse cutaneous forms, as supported by the American College of Rheumatology 1
• Skin fibrosis is a dominant clinical feature, with diffuse cutaneous SSc (dcSSc) characterized by skin thickening proximal to elbows/knees and on trunk, and limited cutaneous SSc (lcSSc) characterized by skin thickening limited to areas distal to elbows/knees, may include face and neck, with a modified Rodnan skin score (mRSS) used to measure skin thickness, ranging from 0-51 1
• Digital ulcers affect approximately 15% of patients and can lead to complications including gangrene, osteomyelitis, and amputation, with a higher risk in patients with secondary Raynaud's phenomenon 1
• Interstitial lung disease (ILD) is present in 40-75% of patients, with a higher frequency in patients with anti-topoisomerase 1 (Scl-70) antibodies, and is progressive in 15-18% of cases 1
• Pulmonary arterial hypertension (PAH) is a complication of scleroderma, with a higher risk in patients with longer disease duration, older age, low diffusing capacity, and screening includes echocardiography, pulmonary function testing, NT-proBNP, 6-minute walking test, as recommended by the American College of Rheumatology 1
• Scleroderma renal crisis (SRC) is more common in early dcSSc, with risk factors including anti-RNA polymerase III antibodies, male sex, tendon friction rubs, rapidly progressive skin involvement, and glucocorticoid use, and requires regular blood pressure monitoring, as supported by the European League Against Rheumatism 1

Monitoring and Follow-up

• Patients with MCTD-PAH require regular monitoring of functional capacity (WHO functional class), serial echocardiographic assessments, and periodic right heart catheterization to evaluate treatment response 3
• Digital sympathectomy and fat grafting can be considered to promote healing of digital ulcers in patients with Raynaud's phenomenon, as recommended by the American College of Rheumatology, with surgical options, such as decompression of thoracic outlet and resection of compressing structures, used for severe cases of thoracic outlet syndrome that do not respond to conservative management, including physical therapy, manual therapy techniques, and botulinum toxin injections, as supported by the European League Against Rheumatism 1, 10